This article was originally published in The Gray Sheet
Proposed sale price of I-Flow's InfuSystem infusion pump distribution subsidiary is reduced from $140 million to $100 million, plus a $12 million "earn out payment," under a memorandum of intent with purchaser HAPC, the firms announce Sept. 12. The price cut "reflects the realities of today's economic environment and the marketplace," explains I-Flow CEO Donald Earhart. The planned divestiture was announced last September to allow I-Flow to focus on its On-Q pain drug-delivery devices (1"The Gray Sheet" Oct. 9, 2006, p. 11)
You may also be interested in...
I-Flow's divestiture of its infusion pump distribution subsidiary InfuSystem for $140 mil. will help fund clinical trials and market share expansion efforts for its On-Q infusion system, the firm says
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.